Login to Your Account



Novo Snags Xellia for $700M; Continues Investment Strategy

By Cormac Sheridan
Staff Writer

Wednesday, May 22, 2013
The growth equity arm of Novo A/S has clocked up its first major pharmaceutical investment, a $700 million buyout of generic antibiotics developer and manufacturer Xellia Pharmaceuticals AS, under a new investment strategy it formulated more than a year ago.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription